Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:01 16/05/2024 BST			5-day change	1st Jan Change
29.28 ^USD	-1.41%		-6.39%	-9.35%

04-30	Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	MT
04-30	Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024

Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024

April 30, 2024 at 12:05 pm

Harmony Biosciences Holdings, Inc. reiterated revenue guidance for the year 2024. For the period, the company expects net product revenue of $700 million to $720 million.

Latest news about Harmony Biosciences Holdings, Inc.

Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	04-30	MT
Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024	04-30
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	04-30	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q1 EPS $0.88, vs. Street Est of $0.78	04-30	MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	04-30	CI
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	04-11	MT
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	04-03	MT
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	04-03	CI
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	03-19	MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:35 PM	03-12
Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	02-27	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	02-23	MT
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	02-22	MT
Transcript : Harmony Biosciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	02-22	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q4 EPS $0.73, vs. Street Est of $0.91	02-22	MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024	02-22	CI
North American Morning Briefing : Nvidia Ignites -2-	02-22	DJ
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application	02-21	MT
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® in Pediatric Narcolepsy	02-21	CI
Harmony Biosciences' Pitolisant Gets FDA's Orphan Drug Designation for Prader-Willi Syndrome	02-20	MT
Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome	02-20	DJ

Chart Harmony Biosciences Holdings, Inc.

Duration

Period

Chart Harmony Biosciences Holdings, Inc.

More charts

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Sector

Pharmaceuticals

Calendar

29/05/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harmony Biosciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.31 USD

Average target price

42.25 USD

Spread / Average Target

+44.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARMONY BIOSCIENCES HOLDINGS, INC.	-9.35%	1.66B
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+30.50%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+15.00%	239B
NOVARTIS AG	+10.00%	209B
ROCHE HOLDING AG	-3.68%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals